-
-
[1] LiawYF , LeungN , GuanR , etal.Asian-PacificconsensusstatementonthemanagementofchronichepatitisB :anupdate[J].JGastroenterolHepatol, 2003, 18∶239-245. [2]姚光弼, 王宝恩, 崔振宇, 等.拉米夫定治疗慢性乙型肝炎三年疗效观察[J], 中华内科杂志, 2003, 42∶383-387. [3]拉米夫定临床应用专家指导小组.2000年拉米夫定临床应用指导意见[J].中华肝脏病杂志, 2000, 8∶249-250. [4] 拉米夫定临床应用专家指导小组.2003年拉米夫定临床应用专家共识[J].中华传染病杂志, 2003, 21∶301-304. [5] TheEASLJury.EASLinternationalconsensusconferenceonhepatitisB[J].JHepatol, 2003, 38∶533-540. [6] LokAS , McMahonBJ.ChronichepatitisB[J].Hepatology, 2001, 34∶1225-1241. [7] LiLL , ChunTW , YinML , etal.Prophylacticlamivudinepreventshep atitisBreactivationandmortalityinpatientsreceivingimmunosuppressionandchemotherapy[J].Hepatology, 2000, 32 (Pt2) ∶1183. [8] LiawYF , SungJJY .ChowWC .etal.EffectsoflamivudineondiseaseprogressionanddevelopmentoflivercancerinadvancedchronichepatitisB :aprospectivedouble-blinedplacebo-controlledclinicaltrial[J].Hepatology, 2003, 38 (Suppl) 1∶262A . [9] FontanaRJ.MangementofpatientswithdecompensatedHBVcirrhosis[J].Seminarsinliverdisease.2003, 23∶89-100. [10] HomX , LittleNR , GardnerSD , etal.PredictorsofvirologicresponsetoLamivudinetreatmentinchildrenwithchronichepatitisBinfection[J].PediatrInfectDisJ, 2004, 23∶441-445. [11] JonasMM , KelleyDA , MizerskiJ , etal.ClinictrialoflamivudineinchildrenwithchronichepatitisB[J].NEngJMed, 2002, 346∶1706-1713. [12] SokalEM .DrugtreatmentofpediatricchronichepatitisB[J].PaediatrDrugs.2002, 4∶361-369. [13]姚光弼, 崔振宇, 姚集鲁, 等.国产拉米夫定治疗2200例慢性乙型肝炎的Ⅳ期临床试验[J].中华肝脏病杂志, 2003, 11∶103-108. [14] DienstagJL , CianciaraJ, KarayalcinS , etal.DurabilityofserologicresponseafterlamivudinetreatmentofchronichepatitisB[J].Hepatolo gy, 2003, 37∶748-755. [15] SchiffER , LaiCL , HadziyannisS , etal.Adefovirdipivoxiltherapyforlamivudine-resistanthepatitisBinpre-andpost-livertransplan-tationpatients[J].Hepatology, 2003, 38∶1419-1427. [16] LiawYF , LeungNW , ChangTT , etal.EffectsofextendedlamivudinetherapyinAsianpatientswithchronichepatitisB[J].Gastroenterology, 2000, 119∶172-180. [17] ChangTT , LaiCL , LiawYF , etal.IncrementalincreasesinHBeAgseroconversionandcontinuedALTnormalizationinAsianchronicHBV (CHB) patientstreatedwithlamivudineforfouryears[J].AntiviralTherapy, 2000, 5 (Suppl1) ∶44. [18] SongBC , SuhDJ, LeeHC , etal.HepatitisBeantigenseroconversionafterlamivudinetherapyisnotdurableinpatientswithchronichepatitisBinKorea[J].Hepatology, 2000, 32∶803-806. [19] HonkoopP , deManRA , NiestersHG , etal.AcuteexacerbationofchronichepatitisBvirusinfectionafterwithdrawaloflamivudinetherapy[J].Hepatology, 2000, 32∶635-639. [20] KobayashiS , IdeT , SataM , etal.DetectionofYMDDmotifmutationsinsomelamivudine-untreatedasymptomatichepatitisBviruscarriers[J].JHepatol, 2001, 34∶584-586. [21]KirishimaT , OkanoueT , DaimonY , etal.DetectionofYMDDmutantusinganovelsensitivemethodinchronicliverdiseasetypeBpatientsbe foreandduringlamivudinetreatment[J].JHepatol, 2002, 37∶259-265. [22] ZhangXX , LiuCM , GongQM , etal.Evolutionofwildtypeandmu tantsoftheYMDDmotifofhepatitisBviruspolymeraseduringlamivudinetherapy[J].JGastroenteroloHepatolo, 2003, 1353-1357. [23] SchalmSW , HeathcoteJ, CianciaraJ , etal.Lamivudineandalphain terferoncombinationtreatmentofpatientswithchronichepatitisBinfec tion:arandomisedtrial[J].Gut, 2000, 46∶562-568. [24] MariaButi, RafaelEsteban.Entecavir, FTC , L -RMAU , LdTandothers[J].JHepatol, 2003, 39∶S139-S142.
本文二维码
计量
- 文章访问数: 1885
- HTML全文浏览量: 4
- PDF下载量: 940
- 被引次数: 0